NZ628627A - Substituted chroman compounds as calcium sensing receptor modulators - Google Patents

Substituted chroman compounds as calcium sensing receptor modulators

Info

Publication number
NZ628627A
NZ628627A NZ628627A NZ62862713A NZ628627A NZ 628627 A NZ628627 A NZ 628627A NZ 628627 A NZ628627 A NZ 628627A NZ 62862713 A NZ62862713 A NZ 62862713A NZ 628627 A NZ628627 A NZ 628627A
Authority
NZ
New Zealand
Prior art keywords
calcium sensing
receptor modulators
methyl
compounds
sensing receptor
Prior art date
Application number
NZ628627A
Other languages
English (en)
Inventor
Manojkumar Ramprasad Shukla
Ankush Gangaram Sarde
Rajeshkumar Maganlal Loriya
Vipul Dilip Pachpute
Navnath Bajirao Walke
Talha Hussain Khan
Sanjeev Anant Kulkarni
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Atlantis Holdings Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Atlantis Holdings Sa filed Critical Lupin Atlantis Holdings Sa
Publication of NZ628627A publication Critical patent/NZ628627A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
NZ628627A 2012-02-24 2013-02-22 Substituted chroman compounds as calcium sensing receptor modulators NZ628627A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN178KO2012 2012-02-24
IN1030KO2012 2012-09-07
PCT/IB2013/051445 WO2013124828A1 (en) 2012-02-24 2013-02-22 Substituted chroman compounds as calcium sensing receptor modulators

Publications (1)

Publication Number Publication Date
NZ628627A true NZ628627A (en) 2017-02-24

Family

ID=54261188

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ628627A NZ628627A (en) 2012-02-24 2013-02-22 Substituted chroman compounds as calcium sensing receptor modulators

Country Status (44)

Country Link
US (3) US9163001B2 (OSRAM)
EP (1) EP2817299B1 (OSRAM)
JP (1) JP6114316B2 (OSRAM)
KR (1) KR102041154B1 (OSRAM)
CN (1) CN104350047B (OSRAM)
AP (1) AP2014007919A0 (OSRAM)
AR (1) AR090135A1 (OSRAM)
AU (1) AU2013223715B2 (OSRAM)
BR (1) BR112014021133B1 (OSRAM)
CA (1) CA2864332C (OSRAM)
CL (1) CL2014002218A1 (OSRAM)
CO (1) CO7160018A2 (OSRAM)
CR (1) CR20140424A (OSRAM)
CU (1) CU24325B1 (OSRAM)
CY (1) CY1122017T1 (OSRAM)
DK (1) DK2817299T3 (OSRAM)
DO (1) DOP2014000193A (OSRAM)
EA (1) EA026940B9 (OSRAM)
ES (1) ES2743492T3 (OSRAM)
GE (1) GEP20186911B (OSRAM)
GT (1) GT201400179A (OSRAM)
HR (1) HRP20191606T1 (OSRAM)
HU (1) HUE046172T2 (OSRAM)
IL (1) IL234252A (OSRAM)
IN (1) IN2014MN01672A (OSRAM)
LT (1) LT2817299T (OSRAM)
MA (1) MA35937B1 (OSRAM)
MX (1) MX355670B (OSRAM)
MY (1) MY171374A (OSRAM)
NI (1) NI201400094A (OSRAM)
NZ (1) NZ628627A (OSRAM)
PE (1) PE20142281A1 (OSRAM)
PH (1) PH12014501891B1 (OSRAM)
PL (1) PL2817299T3 (OSRAM)
PT (1) PT2817299T (OSRAM)
RS (1) RS59172B1 (OSRAM)
SG (1) SG11201405117SA (OSRAM)
SI (1) SI2817299T1 (OSRAM)
SM (1) SMT201900506T1 (OSRAM)
TN (1) TN2014000352A1 (OSRAM)
TW (1) TWI617549B (OSRAM)
UA (1) UA112679C2 (OSRAM)
WO (1) WO2013124828A1 (OSRAM)
ZA (1) ZA201405990B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201405117SA (en) * 2012-02-24 2014-09-26 Lupin Ltd Substituted chroman compounds as calcium sensing receptor modulators
WO2014033604A1 (en) * 2012-08-27 2014-03-06 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
AU2014313835A1 (en) 2013-08-28 2016-03-03 Lupin Atlantis Holdings Sa Substituted naphthalene compounds as calcium sensing receptor modulators
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
WO2017037616A1 (en) 2015-08-31 2017-03-09 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
WO2021100059A1 (en) * 2019-11-19 2021-05-27 Lupin Limited Process for preparing chroman compounds
BR112022012663A2 (pt) * 2019-12-27 2022-09-06 Lupin Ltd Composição farmacêutica de moduladores de casr e métodos e usos da mesma
CN114981253B (zh) * 2020-01-17 2024-06-18 印度鲁宾有限公司 制备苯并二氢吡喃化合物的工艺和中间体及其方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3063585D1 (en) * 1979-05-19 1983-07-07 Beecham Group Plc Chroman derivatives, processes for their preparation and pharmaceutical compositions containing them
US5387587A (en) * 1986-12-23 1995-02-07 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
US6133277A (en) 1997-12-05 2000-10-17 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
US7105537B2 (en) 2003-01-28 2006-09-12 Bristol-Myers Squibb Company 2-substituted cyclic amines as calcium sensing receptor modulators
EP1630157A4 (en) 2003-05-28 2007-05-23 Japan Tobacco Inc ANTAGONIST OF CASR
WO2006123725A1 (ja) 2005-05-19 2006-11-23 Astellas Pharma Inc. ピロリジン誘導体またはその塩
TW200815388A (en) 2006-04-18 2008-04-01 Wyeth Corp Chromane and chromene derivatives and uses thereof
KR101129868B1 (ko) 2006-10-04 2012-04-12 화이자 프로덕츠 인코포레이티드 칼슘 수용체 길항제로서의 피리도[4,3-d]피리미딘-4(3H)-온 유도체
JP5470653B2 (ja) * 2006-10-26 2014-04-16 アムジエン・インコーポレーテツド カルシウム受容体調節剤
WO2008059854A1 (en) 2006-11-16 2008-05-22 Astellas Pharma Inc. Piperidine derivatives or salts thereof
AU2008311974B2 (en) * 2007-10-15 2013-11-21 Amgen Inc. Calcium receptor modulating agents
RU2524949C2 (ru) 2007-11-23 2014-08-10 Лео Фарма А/С Новые циклические углеводородные соединения для лечения заболеваний
CN102239136B (zh) 2008-10-03 2014-09-17 味之素株式会社 CaSR激动剂
WO2010042642A1 (en) 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
EP2435404A1 (en) 2009-05-27 2012-04-04 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010150837A1 (ja) 2009-06-25 2010-12-29 第一三共株式会社 インドリン誘導体
EP2643292A1 (en) 2010-11-26 2013-10-02 Leo Pharma A/S Calcium-sensing receptor-active compounds
JP2014500882A (ja) 2010-11-26 2014-01-16 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
JP2014508103A (ja) 2010-11-26 2014-04-03 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
US9382216B2 (en) 2011-03-10 2016-07-05 Lupin Limited Substituted morpholines as modulators for the calcium sensing receptor
EP2686306B1 (en) 2011-03-18 2017-01-04 Lupin Atlantis Holdings SA Benzo[b][1,4]oxazin derivatives as calcium sensing receptor modulators
SG11201405117SA (en) * 2012-02-24 2014-09-26 Lupin Ltd Substituted chroman compounds as calcium sensing receptor modulators

Also Published As

Publication number Publication date
NI201400094A (es) 2015-03-27
PE20142281A1 (es) 2015-01-16
CN104350047B (zh) 2017-05-24
AR090135A1 (es) 2014-10-22
EA201491582A1 (ru) 2014-12-30
BR112014021133A2 (pt) 2018-09-11
DK2817299T3 (da) 2019-09-16
PH12014501891A1 (en) 2015-02-09
EP2817299B1 (en) 2019-06-12
US20150368222A1 (en) 2015-12-24
TN2014000352A1 (en) 2015-12-21
BR112014021133B1 (pt) 2022-06-28
HRP20191606T1 (hr) 2019-12-13
CY1122017T1 (el) 2020-10-14
CA2864332A1 (en) 2013-08-29
CL2014002218A1 (es) 2015-03-06
JP6114316B2 (ja) 2017-04-12
CO7160018A2 (es) 2015-01-15
GT201400179A (es) 2016-03-01
US9598391B2 (en) 2017-03-21
HK1205117A1 (en) 2015-12-11
IL234252A (en) 2017-02-28
MY171374A (en) 2019-10-10
US9163001B2 (en) 2015-10-20
TWI617549B (zh) 2018-03-11
GEP20186911B (en) 2018-10-25
KR102041154B1 (ko) 2019-11-07
EP2817299A1 (en) 2014-12-31
SMT201900506T1 (it) 2019-11-13
KR20140135731A (ko) 2014-11-26
WO2013124828A1 (en) 2013-08-29
AU2013223715B2 (en) 2017-09-14
AU2013223715A1 (en) 2014-08-28
US20170209410A1 (en) 2017-07-27
AP2014007919A0 (en) 2014-09-30
CA2864332C (en) 2020-08-25
CU24325B1 (es) 2018-03-13
LT2817299T (lt) 2019-09-25
US9987249B2 (en) 2018-06-05
MX355670B (es) 2018-04-25
ZA201405990B (en) 2015-11-25
EA026940B1 (ru) 2017-06-30
DOP2014000193A (es) 2017-01-15
CU20140103A7 (es) 2015-01-29
JP2015508097A (ja) 2015-03-16
SG11201405117SA (en) 2014-09-26
EA026940B9 (ru) 2017-11-30
ES2743492T3 (es) 2020-02-19
IN2014MN01672A (OSRAM) 2015-05-29
CR20140424A (es) 2015-01-13
SI2817299T1 (sl) 2019-10-30
PT2817299T (pt) 2019-09-23
PH12014501891B1 (en) 2021-05-05
TW201336831A (zh) 2013-09-16
US20150038546A1 (en) 2015-02-05
UA112679C2 (uk) 2016-10-10
MA35937B1 (fr) 2014-12-01
PL2817299T3 (pl) 2019-12-31
MX2014010139A (es) 2015-09-04
HUE046172T2 (hu) 2020-02-28
CN104350047A (zh) 2015-02-11
RS59172B1 (sr) 2019-10-31

Similar Documents

Publication Publication Date Title
NZ628627A (en) Substituted chroman compounds as calcium sensing receptor modulators
UA112973C2 (uk) Складноефірні проліки [3-(1-(1h-імідазол-4-іл)етил)-2-метилфеніл]метанолу
JO3297B1 (ar) تركيبات و طرق لتعديل fxr
EA201390969A1 (ru) Модуляторы глюкагонового рецептора
EA201490320A1 (ru) Соединения тетрагидропиридопиридина и тетрагидропиридопиримидина и их применение в качестве модуляторов рецептора c5a
BR112016006151A2 (pt) imidazopiridazinas úteis como inibidores da via de sinalização do par-2
EP4268814A3 (en) Pharmaceutical composition for the treatment of dry eye
EA201390683A1 (ru) Пиперидинонкарбоксамидазаинданы - антагонисты рецептора cgrp
EA201391797A1 (ru) 3-спироциклические пиперидиновые производные в качестве агонистов грелиновых рецепторов
WO2009147170A3 (en) Drug combinations comprising a dgat inhibitor and a ppar-agonist
EA201190004A1 (ru) Конденсированные имидазол карбоксамиды в качестве модуляторов trpv3
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
JOP20130213B1 (ar) معارضات لمستقبلht3-5
MX390264B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
EA201001094A1 (ru) Производные индазола
MX2012006022A (es) Compuestos novedosos como moduladores de receptor con utilidad terapeutica.
EA201100696A1 (ru) 1-(арилсульфонил)-4-(пиперазин-1-ил)-1h-бензимидазолы в качестве лигандов 5-гидрокситриптамина-6
WO2011050054A3 (en) Coumarin compounds as receptor modulators with therapeutic utility
HK1218543A1 (zh) 新型磺酰胺trpa1受体拮抗剂
MX339858B (es) Compuestos novedosos como ligandos del receptor h3 de la histamina.
UA117154C2 (uk) Антагоністи s1p3
NZ630816A (en) N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique
MA32479B1 (fr) Compoés nouveaux actifs comme antagonistes des recepteurs muscariniques
EA201491105A1 (ru) Циклические производные мочевины в качестве антагонистов андрогенных рецепторов

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: LUPIN ATLANTIS HOLDING, CH

Effective date: 20160922

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 22 FEB 2020 BY WRAYS

Effective date: 20170726

ASS Change of ownership

Owner name: LUPIN LIMITED, IN

Effective date: 20180209

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 FEB 2021 BY WRAYS PTY LTD

Effective date: 20200121

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 FEB 2022 BY WRAYS PTY LTD

Effective date: 20210212

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 FEB 2023 BY WRAYS PTY LTD

Effective date: 20220207

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 FEB 2024 BY CPA GLOBAL

Effective date: 20230127

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 FEB 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240125

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 FEB 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250206